The Episeras (formerly mjn-SERAS) device, developed by German specialty drugmaker Neuraxpharm and Spanish digital health ...

Episeras is a Bluetooth-enabled earpiece with a custom-designed, 3D-printed brain activity sensor which monitors for ...

To find out, pharmaphorum chatted with Jack Kreindler (WellFounded) after his onstage session at Frontiers Health 2025.

UK researchers have developed a platform that can test whether commercial AI algorithms developed for NHS applications are ...

The FDA has started a priority review of BeOne Medicines' BCL2 inhibitor sonrotoclax in relapsed or refractory mantle cell ...

YourCoach Health’s Eugene and Marina Borukhovich spoke with pharmaphorum after their Frontiers Health session to get to the ...

The attraction for Alkermes and Lundbeck in Avadel is Lumryz, an extended-release formulation of the well-established ...

A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for hereditary haemorrhagic telangiectasia (HHT), the second most common inherited ...

Kelonia Therapeutics only started human testing of its in vivo CAR-T therapy for multiple myeloma in August, but already has ...

Sanofi is being probed for 'money laundering of tax fraud', 'money laundering of tax fraud by an organised or aggravated ...

Novo Nordisk said it will now move ahead with a phase 3 programme for both versions of the drug in adults with type 2 ...

The new intrathecal formulation means the one-shot gene therapy is now available to all SMA patients, regardless of their age ...